Important Appointments Made at Janssen Türkiye

Key Appointments Made at Janssen Turkey Dr. Çağatay Keleş has been appointed Director of the Central Nervous System (CNS) & Pulmonary Arterial Hypertension (PAH) & Rare Metabolic Diseases (RMD) Business Unit at Janssen Turkey, the pharmaceutical division of Johnson & Johnson, one of the world's largest healthcare companies. Berkin Gökbudak has been appointed Director of the Oncology & Hematology Business Unit. With these new appointments, Janssen Turkey continues to strengthen its leadership team. Operating in Turkey for nearly a quarter century, Janssen has built strong partnerships with public institutions, academia and healthcare professionals for public health, and is known for its patient-focused approach and support for employee development across all areas. Two senior appointments have been made at Janssen Turkey.

CNS & PAH & RMD Business Unit Director Dr. Çağatay Keleş

Dr. Çağatay Keleş, appointed as Director of the CNS & PAH & RMD Business Unit at Janssen Turkey, played a key role in establishing the Oncology & Hematology divisions and structuring the healthcare solutions function with diverse perspectives since joining the company in 2008. In addition to leading the PAH & RMD Business Unit, Keleş has now taken on leadership of the CNS Business Unit and will lead teams to reach more patients in these therapeutic areas for Janssen Turkey.

Oncology & Hematology Business Unit Director Berkin Gökbudak

Berkin Gökbudak, who joined Janssen Turkey as Oncology & Hematology Business Unit Leader in September 2021, has been appointed Director of the Oncology & Hematology Business Unit. Gökbudak, who has delivered successful business results in Oncology & Hematology, one of Janssen's key focus areas globally and in Turkey, will continue his work towards healthier living in his new role.